These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 2294381)

  • 41. [Postmarketing surveillance studies in community pharmacies].
    Nieber K; Lehmacher W
    Med Monatsschr Pharm; 2009 Aug; 32(8):301-6. PubMed ID: 19777737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Device user regulations, not user friendly.
    Cooney J
    AOHA; 1991 Jun; 35(6):4. PubMed ID: 10116065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Post-marketing management of the use of non-narcotic analgesics.
    Miettinen OS
    Med Toxicol; 1986; 1 Suppl 1():125-7. PubMed ID: 3821427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Review of product licences.
    Watson J
    Vet Rec; 1987 Oct; 121(17):408. PubMed ID: 3686813
    [No Abstract]   [Full Text] [Related]  

  • 46. 'An urgent remedy needed'.
    Scott S
    Br Dent J; 1992 Mar; 172(5):178. PubMed ID: 1543629
    [No Abstract]   [Full Text] [Related]  

  • 47. [Duties of the physician in the context of the current law on medical products].
    Kaiser RH; Ininger G
    Unfallchirurg; 2003 Mar; 106(3):226-36; quiz 236-7. PubMed ID: 12733501
    [No Abstract]   [Full Text] [Related]  

  • 48. Digital era drug surveillance: Quo vadis, Australia?
    Raubenheimer JE; Barratt MJ
    Drug Alcohol Rev; 2018 Sep; 37(6):693-696. PubMed ID: 30175478
    [No Abstract]   [Full Text] [Related]  

  • 49. Australian and New Zealand governments agree to proceed with the joint regulatory agency for therapeutic products.
    Moore J
    J Law Med; 2011 Dec; 19(2):272-4. PubMed ID: 22320002
    [No Abstract]   [Full Text] [Related]  

  • 50. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
    Ghosh D; Skinner M; Ferguson LR
    Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pharmacologic surveillance and safety of drugs: reflexions for legislative and, especially, cultural action].
    Laporte JR
    Rev Med Univ Navarra; 1988; 32(1):31-3. PubMed ID: 3154929
    [No Abstract]   [Full Text] [Related]  

  • 52. Drug regulation in Australia.
    Med J Aust; 1990 Jan; 152(1):53-4. PubMed ID: 2294381
    [No Abstract]   [Full Text] [Related]  

  • 53. Drug regulation in Australia.
    Hall RC
    Med J Aust; 1989 Sep; 151(6):338-40, 343-6. PubMed ID: 2687666
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.